Drug-coated balloons provide an alternative treatment option for small-vessel coronary artery disease with clinical outcomes comparable to drug-eluting stents across multiple studies.
Do drug-coated balloons reduce restenosis and major adverse cardiac events compared to drug-eluting stents or balloon angioplasty in patients with small-vessel coronary artery disease?
Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option for small-vessel disease, offering comparable outcomes to drug-eluting stents while avoiding foreign-body implantation and potentially shortening dual antiplatelet therapy duration.
Percutaneous coronary intervention of small-vessel coronary artery disease (SVD) remains challenging due to difficulties with device delivery and high restenosis rate, even with the use of newer-generation drug-eluting stents. Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option in patients with SVD. Potential advantages of drug-coated balloons in SVD include enhanced deliverability because of their small profile, avoidance of foreign-body implantation, and shorter duration of dual antiplatelet therapy.
Megaly et al. (Tue,) conducted a review in Small-vessel coronary artery disease. Drug-coated balloons vs. Drug-eluting stents and balloon angioplasty was evaluated. Drug-coated balloons provide an alternative treatment option for small-vessel coronary artery disease with clinical outcomes comparable to drug-eluting stents across multiple studies.